Announced details
Novel monoclonal antibody medicines for dogs and cats; treatment of inflammatory diseases in cats
The company entered into a joint research agreement concerning novel monoclonal antibody medicines for dogs and cats in September 2025, and a license agreement for an antibody to treat inflammatory diseases in cats in March 2026.
Head office: Yokohama, Kanagawa Prefecture; Representative Director: Shinjo Katsuhiro (新庄勝浩). A startup biopharmaceutical company engaged in the research and development of therapeutic monoclonal antibody medicines. It owns the MOURA Library.
The company will pay the contractually specified one-time payment, but the amount has not been disclosed. Additional milestone payments and sales royalties may arise in the future.
The company will incur the contractually specified one-time payment. Additional milestone payments and sales royalties may arise in the future. The medium-term management plan sets a sales KPI for new businesses, including animal health, as a numerical target for the fiscal year ending March 2030, but does not state the amount of the impact of this matter on performance.
The company does not address Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Antibody for treating inflammatory diseases in cats; antibody-based medicines for cats |
| Counterparty | MabGenesis株式会社 |
| Counterparty overview | Head office: Yokohama, Kanagawa Prefecture; Representative Director: Shinjo Katsuhiro (新庄勝浩). A startup biopharmaceutical company engaged in the research and development of therapeutic monoclonal antibody medicines. It owns the MOURA Library. |
| Relationship with the Company | The company entered into a joint research agreement concerning novel monoclonal antibody medicines for dogs and cats in September 2025, and a license agreement for an antibody to treat inflammatory diseases in cats in March 2026. |
| Contract Value | The company will pay the contractually specified one-time payment, but the amount has not been disclosed. Additional milestone payments and sales royalties may arise in the future. |
| Contract Date | September 2025 (joint research agreement); March 2026 (license agreement) |
| Applicable area | Novel monoclonal antibody medicines for dogs and cats; treatment of inflammatory diseases in cats |
| Impact on Business Performance | The company will incur the contractually specified one-time payment. Additional milestone payments and sales royalties may arise in the future. The medium-term management plan sets a sales KPI for new businesses, including animal health, as a numerical target for the fiscal year ending March 2030, but does not state the amount of the impact of this matter on performance. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company achieved a milestone under the license agreement. It stated that it will advance research and development toward the future launch of antibody-based medicines for cats, contributing to the creation of new businesses under its medium-term management plan.